Form 4: Globus Medical Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Globus Medical Director Ann D. Rhoads sold 10,000 shares of Class A Common Stock for a weighted average price of $58.46 per share under a pre-arranged trading plan.
Summary
- Ann D. Rhoads, a Director of Globus Medical Inc. (GMED), reported a sale of Class A Common Stock.
- The transaction involved the disposition of 10,000 shares.
- The shares were sold at a weighted average price of $58.46 per share, with a price range of $58.22 to $58.81.
- The sale was executed on September 15, 2025.
- This transaction was conducted pursuant to a Rule 10b5-1 trading plan, which was established on November 8, 2024.
- Following this transaction, Ann D. Rhoads directly beneficially owns 25,384 shares of Class A Common Stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as this is a routine disclosure of an insider stock sale executed under a pre-arranged 10b5-1 trading plan, which typically mitigates concerns about opportunistic selling.
Positives
- NA
Negatives
- A Director, Ann D. Rhoads, sold 10,000 shares of Class A Common Stock, reducing her direct beneficial ownership in the company.
Risks
- NA
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Management Comments
- NA
Industry Context
This insider transaction report is specific to Globus Medical Inc. and does not provide broader industry trends or competitive analysis.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders may note a reduction in direct insider ownership by a director, though the pre-arranged nature of the sale (10b5-1 plan) suggests it is not based on new, immediate material non-public information.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| November 8, 2024 | Date the Rule 10b5-1 trading plan was established by the reporting person. |
| September 15, 2025 | Date of the reported transaction (sale of Class A Common Stock). |
| September 16, 2025 | Date the Form 4 was signed by the attorney-in-fact. |
Recommendation
holdThis Form 4 reports a pre-scheduled insider sale and does not provide new fundamental information to alter an investment thesis. The transaction is a routine disclosure and does not indicate a change in the company's operational or financial outlook.
Keywords
GMED, Globus Medical, insider trading, Form 4, stock sale, director, 10b5-1 plan, equity transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.